← Compound index
COMPOUND RECORD / CYCLONTANE

CyclontaneЦиклонтан

A synthetic adamantane derivative, also called ADK-638, studied on its own and in a formulation with sodium oxybate.

CognitionPerformanceSleep
Source linked

What the studies found

Animal research · 2022

Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability

Study of multiple preparations

Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.

Study notes · methods, sources and limitations

Participants or model CD-1 mice separated by baseline attention phenotype; three administrations

Important limitations

  • Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement. Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.

Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8 · Publication record

Original source or citation ↗

Study results and tables ↗

Experiment described in a patent · 2018

Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis

Wheel activity
Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900Desynchronized ratsThird day
REM-sleep duration
Reported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM thresholdThreshold: REM duration >50% of the baseline group average
Persisting abnormality
REM-onset latency remained approximately twice baseline; wakefulness remained elevatedImprovement versus injury did not mean normalization

The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.

More reported outcomes
Acute observations
No deaths or listed overt neurological/behavioral abnormalities reportedAnimal observations only14 days
Study notes · methods, sources and limitations

Participants or model Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.

Design Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.

Important limitations

  • Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety. No clinical sleep benefit or safe self-use regimen follows from these experiments.
  • The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.

RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense · Patent report

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Cyclontane

Names in this research collection

ADK-638 · Cyclantane · Циклантан

Research background

1-Hydroxy-4-cyclohexylaminoadamantane hydrochloride (ADK-638), an experimental hydroxyadamantane. Individual-compound experiments and the sodium-oxybate formulation are separate evidence.

Compound class
Experimental adamantane / analogue
Research collection
Actoprotection & occupational pharmacology · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Human efficacy results unavailable

Study methods

Source-specific animal, chemistry, patent or dissertation evidence

Independent replication

Independent replication not established; translations are not separate experiments

Source access

Access and review depth appear with each linked record

Safety evidence

Human safety and interactions not established; animal activity is not a safe-use recommendation

Open a topic for the evidence assessment.

More findings, background and history

Chlodantane, Cyclontane and the ADK research program ↗

What remains unclear

In the 2022 experiment, attention worsened in mice that already performed well. The full methods, safety results and independent replication remain unavailable.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 2 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2018 · RU2674342C2 · Cyclontane and sodium oxybate pharmaceutical composition for desynchronosisUse · Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900

Reported findings

Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.

Wheel activity
Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900Third dayDesynchronized rats
REM-sleep duration
Reported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM thresholdThreshold: REM duration >50% of the baseline group average
All reported results, comparisons and limitations →

Use. Later Cyclontane use claims and experimental support; neither a grant nor a comparator establishes human efficacy.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2674342C2 ↗ · 2018-12-07
Earliest priority / filing
2016-11-28 / 2016-11-28
Original applicant / assignee
Российская Федерация, от имени которой выступает Министерство обороны Российской Федерации
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
62557472 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Pharmaceutical composition of 1-hydroxy-4-cyclohexylaminoadamantane hydrochloride and sodium salt of 4-hydroxymic acid, improving mental and physical efficiency when having desynchronosis

Inventors: Сергей Борисович Середенин; Борис Михайлович Пятин; Нина Ивановна Авдюнина; Любовь Николаевна Грушевская; Надежда Михайловна Зайцева; Константин Викторович Алексеев; Евгения Викторовна Блынская; Анна Сергеевна Михеева; Людмила Михайловна Гаевая; Мария Сергеевна Сергеева; Татьяна Александровна Воронина; Светлана Александровна Литвинова; Инга Геннадиевна Капица; Елена Анатольевна Иванова; Татьяна Сергеевна Калинина.

RU2674342C2

Original patent PDF ↗

Read source review →

2003 · RU2196575C2 · Original Cyclontane / ADK-638 patent trailMolecule · Significantly longer running-to-exhaustion at selected tested exposures

Findings described in words

The patent reports increased running-to-exhaustion performance and stimulant-related behavioral effects.

Treadmill performance
Significantly longer running-to-exhaustion at selected tested exposures8 rats per group; exact table means not transcribed
Behavioral pharmacology
Anti-cataleptic activity and stimulant-like responses describedModel-specific comparisons do not establish human superiority to Bromantane
All reported results, comparisons and limitations →

Molecule. Cyclontane development patent; the compound identity is distinct from related cage amides and comparator agents.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2196575C2 ↗ · 2003-01-20
Earliest priority / filing
1999-07-30 / 1999-07-30
Original applicant / assignee
Научно-исследовательский институт фармакологии РАМН
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20223238 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Substance eliciting psychostimulating and antiasthenic effect

Inventors: С.Б. Середенин; И.С. Морозов; Г.Г. Незнамов; Н.В. Климова; Н.И. Авдюнина; И.А. Иванова; С.А. Сергеева; Г.И. Ковалев; Б.М. Пятин; Е.А. Вальдман; О.А. Михайлова; Н.А. Кисляк; О.В. Щербакова; О.Б. Степаненко; Е.А. Цветкова.

RU2196575C2

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2018

Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis

The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.

Wheel activity · Approximately 700 revolutions with the combination versus 200 with saline; baseline about 900 · Desynchronized rats · Third day

Study notes and original source
2018Patent / reported experimentsFull text available

Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis

Format: Patent · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

· RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense

The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.

Results and tables

Reported patent results

Reported findings

Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.

Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.

Population or model Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.

Results · Description: wheel-running results, sleep-wake narratives around Tables 2–3 and 14-day observation.
MeasureResultComparison, timing and statistics
Wheel activityApproximately 700 revolutions with the combination versus 200 with saline; baseline about 900Desynchronized rats · Third day
REM-sleep durationReported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM thresholdThreshold: REM duration >50% of the baseline group average
Persisting abnormalityREM-onset latency remained approximately twice baseline; wakefulness remained elevatedImprovement versus injury did not mean normalization
Acute observationsNo deaths or listed overt neurological/behavioral abnormalities reportedAnimal observations only · 14 days

The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
  • No clinical sleep benefit or safe self-use regimen follows from these experiments.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2022

Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability

Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.

Study notes and original source
2022Animal / experimentalFull text available

Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability

Format: Journal article; full-text reproduction · Reviewed: Abstract, identity passage and selected methods reviewed

N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev · Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8

Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.

Population / setting
CD-1 mice separated by baseline attention phenotype; three administrations
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
  • Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.

Reviewed 2026-10-03.

Read the source ↗

Experiment described in a patent · 2003

Original Cyclontane / ADK-638 patent trail

The later patent cites this earlier Cyclontane development record. Original behavioral and toxicity comparisons require direct verification before numerical claims are reproduced.

Study notes and original source
2003Patent / reported experimentsBibliographic record

Original Cyclontane / ADK-638 patent trail

· RU2196575C2; cited in later RU2674342C2

The later patent cites this earlier Cyclontane development record. Original behavioral and toxicity comparisons require direct verification before numerical claims are reproduced.

Results and tables

Reported patent results

Findings described in words

The patent reports increased running-to-exhaustion performance and stimulant-related behavioral effects.

Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.

Population or model Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.

Results · Treadmill and anti-catalepsy experiments, Tables 5–6 narrative.
MeasureResultComparison, timing and statistics
Treadmill performanceSignificantly longer running-to-exhaustion at selected tested exposures8 rats per group; exact table means not transcribed
Behavioral pharmacologyAnti-cataleptic activity and stimulant-like responses describedModel-specific comparisons do not establish human superiority to Bromantane

Preselected animal performance is not a human occupational outcome, and the patent’s clinical recommendations exceed the experiments. Findings belong to ADK-638 rather than every related cage compound.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.
Source reviewed
Prior-art citation followed from the 2018 patent; original retrieval unsuccessful.
Study limitations
  • Bibliographic lead only; neither potency ratios nor toxicity estimates from secondary accounts are treated as verified here.

Reviewed 2026-11-06.

Read the source ↗

Explore related historical combinations ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗